Aug. 17 at 5:26 PM
$IOVA $CRVS
Apply This to CRVS (Corvus Pharmaceuticals):
Let’s spin the same format but for CRVS and dermatitis except we need to answer this first:
Is CRVS’s candidate for atopic dermatitis (AD) being studied as a:
• 🥇 1st line (1L) therapy (before Dupixent)?
• 🥈 2nd line (2L) (after Dupixent failure)?
• Or a niche rescue for refractory or steroid-intolerant populations?
This matters hugely for perceived value
